Evidence map›Paper›PMID 41878531›Full record

ArticleFrontiers in oncology2026

Prostatic carcinoma with elevated carcinoembryonic antigen: a case report.

Zhi-Xin Xie, Ai-Ming Yang, Qiang Wang

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhi-Xin XieDepartment of Clinical Medicine, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Ai-Ming YangDepartment of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Qiang WangDepartment of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinoembryonic antigen is a glycoprotein often associated with colorectal carcinoma but can also increase in other malignancies. We reported a rare case of prostate mucinous adenocarcinoma in a 69-year-old male with elevated carcinoembryonic antigen and normal prostate-specific antigen. The patient, with a history of benign prostatic hyperplasia, was initially asymptomatic apart from an elevated carcinoembryonic antigen detected during routine examination. Comprehensive evaluations, including colonoscopy, CT and PET/CT, yielded no conclusive findings. However, a pelvic MRI later revealed an irregular prostatic mass, and a biopsy confirmed adenocarcinoma with mucinous features. Carcinoembryonic antigen positivity was further demonstrated by immunohistochemistry on the specimen. This case highlights that isolated carcinoembryonic antigen elevation, even in the absence of prostate-specific antigen elevation, may warrant consideration of prostatic carcinoma in differential diagnosis, particularly in the absence of colorectal carcinoma history. Elevated carcinoembryonic antigen levels should prompt further investigation, as they may serve as an early marker for prostatic malignancies when followed by targeted imaging and histological confirmation.

Indexed as

carcinoembryonic antigendiagnostic markersearly diagnosis of prostatic carcinomaprostate-specific antigenprostatic carcinoma

Identifiers

PMID41878531
PMCPMC13006275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.